[1]杨 灡,孙妲男,李 勇,等.解毒活血汤对慢性肾脏病大鼠肾脏Smad2、Smad3表达的影响[J].陕西中医,2025,46(1):19-24.[doi:DOI:10.3969/j.issn.1000-7369.2025.01.004]
　YANG Lan,SUN Danan,LI Yong,et al.Effects of Jiedu Huoxue decoction on CKD rat kidney Smad2,Smad3[J].,2025,46(1):19-24.[doi:DOI:10.3969/j.issn.1000-7369.2025.01.004]
点击复制

解毒活血汤对慢性肾脏病大鼠肾脏Smad2、Smad3表达的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年1期
页码:
19-24
栏目:
基础研究
出版日期:
2025-01-05

文章信息/Info

Title:
Effects of Jiedu Huoxue decoction on CKD rat kidney Smad2,Smad3
作者:
杨 灡1; 孙妲男2; 李 勇2; 徐 丽2; 周 鹏1; 代 璇1; 侯 兴1; 褚宇鹏1; 李敬槟1
(1.黑龙江中医药大学研究生院,黑龙江 哈尔滨 150040; 2.黑龙江中医药大学附属第二医院肾内科,黑龙江 哈尔滨 150001)
Author(s):
YANG Lan; SUN Danan; LI Yong; XU Li; ZHOU Peng; DAI Xuan; HOU Xing; CHU Yupeng; LI Jingbing
(Graduate School of Heilongjiang University of Traditional Chinese Medicine,Harbin 150040,China)
关键词:
慢性肾脏病;  解毒活血汤;  大鼠;  去宛陈莝;  免疫组化法;  Smad2;  Smad3
Keywords:
Chronic kidney disease;  Jiedu Huoxue decoction;  Rats;  Quwan Chencuo;  Immunohistochemical method;  Smad2 protein;  Smad3 protein
分类号:
R 692
DOI:
DOI:10.3969/j.issn.1000-7369.2025.01.004
文献标志码:
A
摘要:
目的:观察解毒活血汤通过调控慢性肾脏病(CKD)大鼠Smads蛋白在肾脏组织中的表达对CKD的作用。方法:将72只雄性SD大鼠随机分成六组,空白组、模型组、阳性对照组,中药低剂量组、中药中剂量组以及中药高剂量组,每组各12只。除空白组外,其余组的大鼠均通过腺嘌呤悬浮液灌胃并饲喂高磷饮食以建立CKD大鼠模型,造模8周后开始对大鼠进行为期12周的药物灌胃处理,在第12周末,对大鼠血液样本进行肌酐(Scr)、尿素氮(BUN)、磷(P)和血钙(Ca)的生化检测,并用免疫组化法分析肾组织中Smad2、Smad3蛋白的表达。结果:与空白组相比,其余组大鼠血清中的Scr、BUN、P和Ca含量均有显著性差异(P<0.01或P<0.05); 与模型组相比,其余组大鼠血清中的Scr、BUN和P的含量普遍降低(P<0.05或P<0.05),而Ca含量则有所上升(P<0.05); 与空白组相比,其余组大鼠肾组织中Smad2和Smad3的表达显著增加(P<0.05)。与模型组相比,其余组肾组织中Smad2和Smad3的表达均有所降低(P<0.05)。相较于解毒活血汤低剂量组,高剂量组、中剂量组及阳性对照组的Smad2蛋白和Smad3蛋白表达量均进一步下降(P<0.05)。结论:解毒活血汤显示出对延缓CKD进程的积极作用,并能有效升高肾组织中Smad2、降低Smad3的表达。相较于其余用药组,解毒活血汤高剂量组展现出更显著的疗效,药物剂量与疗效之间存在正相关关系。
Abstract:
Objective:To observe the effect of Jiedu Huoxue decoction on chronic kidney disease(CKD)by regulating the expression of Smads protein in kidney tissues of rats with CKD. Methods:Seventy-two male SD rats were randomly divided into six groups,the blank group,the model group,the positive control group,the low-dose group of traditional Chinese medicine,the medium-dose group of traditional Chinese medicine,and the high-dose group of traditional Chinese medicine,with 12 rats in each group.Except for the blank group,the rats in the other groups were gavaged with adenine suspension and fed a high-phosphorus diet to establish a CKD rat model,and the rats were treated with the drug by gavage for a period of 12 weeks after the modeling period of 8 weeks.On the 12th weekend,biochemical tests were conducted on rat blood samples for creatinine(Scr),urea nitrogen(BUN),phosphorus(P),blood calcium(Ca). On the 12th weekend,expression of Smad2 and Smad3 proteins in the kidney tissues.Results:Comparison of data between groups was made after completing the whole process of drug administration and analysis.Compared with the blank group,the serum levels of Scr,BUN,P and Ca in the remaining groups of rats were significantly different(P<0.01 or P<0.05); compared with the model group,the serum levels of Scr,BUN and P in the remaining groups of rats were generally decreased(P<0.05 or P<0.05),while Ca levels were increased(P<0.05).Compared with the blank group,the remaining groups of The expression of Smad2 and Smad3 in rat kidney tissues was significantly increased(P<0.05).Compared with the model group,the expression of Smad2 and Smad3 in the kidney tissues of the rest of the groups were decreased(P<0.05).Compared with the low-dose group of detoxification and activation of blood circulation soup,the expression of Smad2 protein and Smad3 protein in the high-dose group,middle-dose group and positive control group were further decreased(P<0.05).Conclusion:Jiedu Huoxue decoction shows a positive effect on delaying the process of CKD and effectively elevated the expression of Smad2 and decreased Smad3 in renal tissues.Compared with the rest of the medication groups,the high dose group of Jiedu Huoxue decoction demonstrated more significant efficacy,and the results of the study showed that there is a positive correlation between the drug dose and the efficacy.

参考文献/References:

[1] 姚律,黄小抗,朱琼.慢性肾衰竭患者并发心血管疾病相关危险因素分析[J].陕西医学杂志,2024,53(1):55-58,63.
[2] KANBAY M,ONAL E M,AFSAR B,et al.The crosstalk of gut microbiota and chronic kidney disease:Role of inflammation,proteinuria,hypertension,and diabetes mellitus[J].Int Urol Nephrol,2018,50:1453-1466.
[3] SUN Y B,QU X,CARUANA G,et al.The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis[J].Differentiation,2016,92(3):102-107.
[4] WANG D D,ZHANG G Y,CHEN X,et al.Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway[J].Int J Mol Med,2018,41(5):2784-2792.
[5] LAN H Y,CHUNG A C.TGF-β/Smad signaling in kidney disease[J].Semin Nephrol,2012,32(3):236-243.
[6] TANG F,HAO Y,ZHANG X,et al.Effect of echinacoside on kidney fibrosis by inhibition of TGF-β1/Smads signaling pathway in the db/db mice model of diabetic nephropathy[J].Drug Des Devel Ther,2017,21(11):2813-2826.
[7] MENG X M,CHUNG A C,LAN H Y.Role of the TGF-beta/BMP-7/Smad athways in renal diseases[J].Clin Sci(Lond),2013,124(4):243-254.
[8] GBD Chronic Kidney Disease Collaboration.Global,regional,and national burden of chronic kidney disease,1990-2017:A systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2020,395(10225):709-733.
[9] LV J C,ZHANG L X.Prevalence and disease burden of chronic kidney disease[J].Adv Exp Med Biol,2019,1165:3-15.
[10] ZHANG L,MIAO R,YU T,et al.Comparative effectiveness of traditional Chinese medicine and angiotensin converting enzyme inhibitors,angiotensin receptor blockers,and sodium glucose cotransporter inhibitors in patients with diabetic kidney disease:A systematic review and network Meta-analysis[J].Pharmacol Res,2022,177:106111.
[11] 周鹏,孙妲男,李勇,等.解毒活血汤对慢性肾脏病大鼠肾脏FGF23、Klotho表达的影响[J].陕西中医,2024,45(1):13-16,22.
[12] 向雨欣,刘小芳,杨庆,等.叶传蕙教授治疗慢性肾脏病运用活血化瘀药的体会[J].云南中医中药杂志,2016,37(8):9.
[13] 李振华,焦安钦.焦安钦辨治慢性肾脏病经验总结[J].中国民族民间医药,2018,27(18):65.
[14] 奚九一.因邪致瘀祛邪为先——论脉管病的诊治思路与方法[J].上海中医药杂志,2001,35(6):4-6.
[15] 张蕾,刘旭生.195例慢性肾脏病3～5期中医证候分布规律探析[J].辽宁中医杂志,2012,39(6):980-983.
[16] 陈飞,柳成刚,常佳怡,等.国医大师张琪教授大方复法临证要诀[J].中华中医药杂志,2018,33(1):136-138.
[17] 许正锦,邱明山,郭宇英,等.慢性肾脏病中医病因病机探讨[J].辽宁中医药大学学报,2011,13(10):137-139.
[18] 曹留洋,余海源.五运六气学说在治疗慢性肾脏病中的应用研究进展[J].陕西中医,2020,41(8):1173.
[19] 郑剑,李勇,于青侠,等.《黄帝内经》“去宛陈莝”理论内涵及应用研究进展[J].中医药学报,2021,49(8):87-90.
[20] 代晓光,张玉梅,刘娜,等.国医大师张琪教授妙用解毒活血汤[J].中国中西医结合肾病杂志,2010,11(12):1046-1047.
[21] 王艳文,李小会,陈丽名,等.活用“去宛陈莝”理论治疗慢性肾衰竭[J].吉林中医药,2022,42(1):28-32.
[22] 乔伟,王丹,孙妲男.“去宛陈莝”法治疗慢性肾功能衰竭[J].中医学报,2022,37(4):705-707.
[23] 王禹霖,刘梦超,郑冰洁,等.名中医张炳厚从瘀论治慢性肾脏病经验撷英[J].陕西中医,2023,44(11):1602-1605.
[24] 张天锡,史磊,刘雯,等.连翘化学成分药理活性现代研究[J].辽宁中医药大学学报,2016,18(12):222-224.
[25] 邹洁,张德德,陶毅,等.葛根素对糖尿病KKAy小鼠氧化应激损伤的干预机制[J].陕西中医,2022,43(3):283-286.
[26] 林飞武,王自善,戎珍,等.柴胡的药理作用化学成分及开发利用研究[J].亚太传统医药,2020,16(10):202-205.
[27] 李小波,彭榜亚,杨江权,等.桃仁红花对UUO大鼠肾组织ILKE-cad FN和α-SMA表达的影响[J].遵义医学院学报,2017,40(2):134-138.
[28] 江宝瑞,丁宏,王跃,等.枳壳的药理研究进展[J].云南中医中药杂志,2022,43(6):70-75.
[29] KRAFFT E,LYBAERT P,ROELS E,et al.Transforming growth factor beta 1 activation,storage,and signaling pathways in idopathic pumonary fibrosis in dogs[J].J Vet Intern Med,2014,28(6):1666-1675.
[30] QIN Z,XIA W,FISHER G J,et al.YAP/TAZ regulates TGF-β/ Smad3 signaling by induction of Smad7 via AP-1 in human skin dermal fibroblasts[J].Cell Commun Signal,2018,16(1):18.

相似文献/References:

[1]屈 凯,王悦彤,王漱非,等.基于文献研究探讨益肾散结法防治肾小球硬化的理论内涵*[J].陕西中医,2019,(7):919.
　QU Kai,WANG Yuetong,WANG Shufei,et al.Based on literature research to explore the theoretical connotation of Kidney-reinforcing and Mass-disintegrating for prevention and treatment of glomerulosclerosis[J].,2019,(1):919.
[2]任永朋,华 琼,刘彦妍,等.中医“治未病”思想在防治肾脏病中的应用*[J].陕西中医,2019,(8):1101.
　REN Yongpeng,HUA Qiong,LIU Yanyan,et al.The application of the thought of “preventive treatment of disease” in the prevention and treatment of kidney disease in traditional Chinese medicine[J].,2019,(1):1101.
[3]张宏强,李桂霞,章彩凤,等.许筠治疗慢性肾病临床药对举隅*[J].陕西中医,2020,(6):808.[doi:DOI:10.3969/j.issn.10007369.2020.06.031]
[4]陈紫薇,陈 明△.从脾论治慢性肾脏病的生物学基础探讨*[J].陕西中医,2020,(11):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
　CHEN Ziwei,CHEN Ming..Discuss the biological foundation for chronic disease therapy from treatment through the spleen[J].,2020,(1):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
[5]董 怡,马 静,余楠楠,等.大黄复方保留灌肠辅助治疗慢性肾脏病疗效及对患者生活质量的影响[J].陕西中医,2021,(7):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
　DONG Yi,MA Jing,YU Nannan,et al.Effect analysis of rhubarb compound retention enema adjuvant treatment of chronic kidney disease and its impact on patients' quality of life[J].,2021,(1):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
[6]齐 宁,宋姝西,刘香玉,等.参芪延肾方治疗慢性肾脏病疗效及对患者半乳糖缺陷IgA1、晚期糖基化终产物和微炎性反应状态的影响[J].陕西中医,2022,(5):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
　QI Ning,SONG Shuxi,LIU Xiangyu,et al.Effects of Shenqi Yanshen recipe on the levels of Gd-IgA1,AGEs and micro inflammatory response in patients with chronic kidney disease[J].,2022,(1):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
[7]麦芳雄,张香兰,朱德礼.温肾健脾清化汤辅助治疗脾肾气虚型慢性肾脏病疗效及对患者血清转化生长因子β1、纤维连接蛋白水平的影响[J].陕西中医,2022,(8):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
　MAI Fangxiong,ZHANG Xianglan,ZHU Deli.Clinical efficacy of Wenshen Jianpi Qinghua decoction in the treatment of chronic kidney disease with spleen-kidney qi deficiency and its effect on serum transforming growth factor β1 and fibronectin levels[J].,2022,(1):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
[8]杨淑彬,李 婷,李晓妮,等.不同中药结肠透析模式对慢性肾脏病患者胃肠道症状和营养状态的影响[J].陕西中医,2022,(12):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
　YANG Shubin,LI Ting,LI Xiaoni,et al.Effects of different colon dialysis modes of traditional Chinese medicine on gastrointestinal symptoms and nutritional status in patients with chronic kidney disease[J].,2022,(1):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
[9]陈 曦,董凯旋,周 荣,等.中药调控p38丝裂原活化蛋白激酶/核因子κB通路治疗肾纤维化研究进展[J].陕西中医,2023,(7):980.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
　CHEN Xi,DONG Kaixuan,ZHOU Rong,et al.Research progress of traditional Chinese medicine regulating p38MAPK/NF-κB pathway in treatment of renal fibrosis[J].,2023,(1):980.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
[10]周 林,禹 红,刘毓玲,等.活肾通络方联合依那普利对慢性肾脏病患者纤维化标志物、人附睾蛋白4水平的影响[J].陕西中医,2023,(10):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]
　ZHOU Lin,YU Hong,LIU Yuling,et al.Effect of Huoshen Tongluo decoction and enalapril on renal function,fibrosis markers and HE4 levels in patients with chronic renal disease[J].,2023,(1):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]
[11]周 鹏,孙妲男,李 勇,等.解毒活血汤对慢性肾脏病大鼠肾脏FGF23、Klotho表达的影响[J].陕西中医,2024,(1):13.[doi:DOI:10.3969/j.issn.1000-7369.2024.01.003]
　ZHOU Peng,SUN Danan,LI Yong,et al.Effects of Jiedu Huoxue decoction on the expression of FGF23 and Klotho in the kidneys of rats with chronic kidney disease[J].,2024,(1):13.[doi:DOI:10.3969/j.issn.1000-7369.2024.01.003]

备注/Memo

备注/Memo:
基金项目:黑龙江省自然科学基金资助项目(LH2021H086); 黑龙江省中医药科研项目(ZHY2020-139,ZHY2022-176); 黑龙江省博士后研究人员落户黑龙江科研启动金资助项目(LBH-Q21190)
更新日期/Last Update: 2025-01-09